Where does Harmony Biosciences Holdings, Inc.'s cash flow data come from?

Every line is extracted from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	$158.69M+9.1%	$145.49M+12.9%	$128.85M-29.0%	$181.47M+425%
Depreciation and amortization	——	$267K-48.1%	$514K+22.7%	$419K+0.7%
Stock-based compensation	$44.9M+5.4%	$42.6M+34.4%	$31.71M+21.1%	$26.17M+67.1%
Deferred income taxes	——	-$29.3M-101%	-$14.54M—	——
Change in accounts receivable	——	——	$19.4M-4.1%	$20.22M+59.6%
Change in inventories	——	——	$1.07M—	——
Change in accounts payable	——	——	$8.97M—	——
Change in other assets	-$31.79M—	——	-$74K-101%	$7.55M—
Change in other liabilities	$67.99M+476%	$11.8M-74.6%	$46.48M—	——
Other working capital changes	$1.33M-36.5%	$2.1M+18.8%	$1.77M+15.9%	$1.53M—
Amortization of intangible assets	$23.85M0.0%	$23.85M0.0%	$23.85M+3.8%	$22.97M+24.6%
Net cash from operating activities	$348.2M+58.4%	$219.82M+0.2%	$219.39M+51.9%	$144.47M+46.6%
Capital expenditures	$310K-73.1%	$1.15M—	——	$172K-42.3%
Purchases of investments	$86.15M-18.2%	$105.29M-17.4%	$127.47M—	——
Proceeds from maturities/sales of investments	$81.06M-17.7%	$98.53M-16.7%	$118.31M—	——
Net cash from investing activities	-$39.65M+41.9%	-$68.23M-46.9%	-$46.44M+67.3%	-$141.83M-41.4%
Repayments of debt	$16.25M+8.3%	$15M+216%	$4.75M+138%	$2M+300%
Proceeds from issuance of common stock	$10.21M+57.0%	$6.5M+28.6%	$5.06M—	——
Taxes paid for net share settlement	$3M—	——	$514K—	——
Net cash from financing activities	-$9.05M+17.7%	-$11M+89.6%	-$105.55M-1,643%	$6.84M-11.5%
Net increase (decrease) in cash	$299.5M—	——	——	——
Interest paid	$14.69M-15.2%	$17.32M-13.6%	$20.05M+22.5%	$16.36M-17.5%
Accretion (Amortization) of Discounts and Premiums, Investments	$1.52M-32.7%	$2.26M-16.7%	$2.72M+528%	$432K—
Adjustment For Amortization Of Debt Issuance Costs	$647K-7.6%	$700K-69.2%	$2.27M—	——
Amortization of capitalized software and acquired intangible assets	$23.85M0.0%	$23.85M0.0%	$23.85M+3.8%	$22.97M+24.6%
Depreciation	——	$267K-48.1%	$514K+22.7%	$419K+0.7%
Depreciation And Impairment Of Long Lived Assets	$1.49M+458%	$267K-48.1%	$514K—	——
In Process Research And Development Acquired	——	——	$2.26M—	——
Accounts payable	——	——	$8.97M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$31.79M—	——	-$74K-101%	$7.55M—
Stock Appreciation Rights Market Adjustment	$65K—	——	——	$772K+73.1%
Payment Of Upfront Fee Investing Activities	$15M-41.2%	$25.5M—	——	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$81.06M-17.7%	$98.53M-16.7%	$118.31M—	——
Free cash flow	$347.89M+59.1%	$218.67M—	——	$144.29M+46.9%
Free cash flow	$347.89M+59.1%	$218.67M—	——	$144.29M+46.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Harmony Biosciences Holdings, Inc.'s cash flow data come from?: Every line is extracted from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.